Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Onconova Therapeutics, Inc. (ONTX)
|
Add to portfolio |
|
|
|
| Price: |
$2.57
| | Metrics |
| OS: |
21.0
|
M
| |
|
|
| Market cap: |
$53.9
|
M
| |
|
|
|
Net cash:
|
|
| |
|
|
|
EV:
|
$53.9
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.2 | 0.2 | 0.2 | 2.2 | 1.2 | 0.8 | 5.5 | 11.5 |
| Revenue growth | 0.0% | -2.2% | -89.4% | 77.8% | 56.0% | -85.8% | -51.6% | 1332.0% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.2 | 0.2 | 0.2 | 2.2 | 1.2 | 0.8 | 5.5 | 11.5 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 11.4 | 7.3 | 16.9 | 15.5 | 16.9 | 19.1 | 20.1 | 25.9 |
| General and administrative | 8.4 | 9.4 | 8.3 | 8.3 | 7.6 | 7.4 | 9.2 | 9.5 |
| EBIT | -19.6 | -16.5 | -25.0 | -21.7 | -23.3 | -24.3 | -27.7 | -24.0 |
| EBIT margin | -8684.5% | -7299.1% | -10819.5% | -994.0% | -1895.9% | -3083.0% | -499.3% | -209.3% |
| Pre-tax income | -19.0 | -16.2 | -25.2 | -21.5 | -20.5 | -24.1 | -19.7 | -24.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | | | 0.6% | | | |
| Net income | -19.0 | -16.2 | -25.2 | -21.5 | -20.6 | -24.1 | -19.7 | -24.0 |
| Net margin | -8391.2% | -7151.8% | -10890.5% | -985.0% | -1675.3% | -3061.2% | -354.6% | -209.3% |
| |
| Diluted EPS | ($0.91) | ($0.96) | ($2.17) | ($1.49) | ($4.99) | ($40.15) | ($4.44) | ($10.54) |
| Shares outstanding (diluted) | 20.9 | 16.8 | 11.6 | 14.4 | 4.1 | 0.6 | 4.4 | 2.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|